Ixekizumab provides superior efficacy compared to ustekinumab over 52-weeks of treatment: results from IXORA-S, a phase 3 study

Carle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich

Research output: Contribution to journalArticlepeer-review

554 Downloads (Pure)

Abstract

BACKGROUND: Biologics targeting interleukin (IL)-17A allow for rapid clearance of psoriatic plaques, with a clinically favorable safety profile.

OBJECTIVES: To compare the safety and efficacy of ixekizumab, an IL-17A antagonist, versus the IL-12/23 inhibitor, ustekinumab, through 52 weeks of treatment in the head-to-head trial, IXORA-S.

METHODS: Patients were randomized to ixekizumab (N=136) or ustekinumab (N=166) and dosed per approved labels. After one year, efficacy was assessed via improvements in Psoriasis Area and Severity Index (PASI; 90% improvement=PASI 90), and static physician global assessment (sPGA) responses of (0) or (0,1), counting drop-outs as non-responders. Safety analyses included treatment-emergent adverse events (TEAEs).

RESULTS: At Week 52, significantly more ixekizumab-treated patients (p<0.01) reported PASI 90 (104, 76.5%), sPGA (0) (72, 52.9%), and sPGA (0,1) (110, 82.1%) responses, compared to ustekinumab-treated patients (PASI 90: 98, 59.0%; sPGA (0): 60, 36.1%; sPGA (0,1): 108, 65.1%). TEAE, serious AEs, and discontinuation rates were not different between the treatment groups. Injection site reactions occurred more frequently in the ixekizumab treatment group (IXE: 22, 16.3%, UST: 2, 1.2%; p<0.001).

LIMITATIONS: This study was not designed to compare safety endpoints related to rare events.

CONCLUSIONS: Ixekizumab showed superior efficacy and comparable safety outcomes versus ustekinumab through 52 weeks of treatment.

Original languageEnglish
JournalJournal of the American Academy of Dermatology
Early online date30 Jun 2018
DOIs
Publication statusPublished - 2018

Fingerprint

Dive into the research topics of 'Ixekizumab provides superior efficacy compared to ustekinumab over 52-weeks of treatment: results from IXORA-S, a phase 3 study'. Together they form a unique fingerprint.

Cite this